Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT) - Takeaways - MDSpire

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • By

  • Maohui Chen

  • Yizhou Huang

  • Shuliang Zhang

  • Cheng Chen

  • Taidui Zeng

  • Hongmu Li

  • Zhenyuan Yang

  • Chuanquan Lin

  • Wei Li

  • Benhua Xu

  • Chun Chen

  • Bin Zheng

  • March 9, 2026

  • 0 min

Share

  • 1

    Neoadjuvant camrelizumab plus radiotherapy achieved high rates of major pathologic response and R0 resection in locally advanced esophageal squamous cell carcinoma.

  • 2

    The study demonstrated very low rates of high-grade toxicity and generally mild postoperative complications, indicating a favorable safety profile.

  • 3

    This phase II trial supports the potential of chemotherapy-sparing neoadjuvant immunoradiotherapy regimens for patients ineligible for standard chemotherapy.

  • 4

    The findings suggest that combining radiotherapy with immune checkpoint inhibitors may enhance treatment efficacy while minimizing systemic toxicity.

  • 5

    The trial's design allowed for early stopping if treatment effects were insufficient, ensuring patient safety and effective monitoring of outcomes.

Original Source(s)

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • by Maohui Chen, Yizhou Huang, Shuliang Zhang, Cheng Chen, Taidui Zeng, Hongmu Li, Zhenyuan Yang, Chuanquan Lin, Wei Li, Benhua Xu, Chun Chen, Bin Zheng

  • March 9, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases